Long-term Efficacy of Vedolizumab for Crohn’s Disease

Vermeire, Séverine; V. Loftus, Edward; Colombel, Jean‐Frédéric; G. Feagan, Brian; J. Sandborn, William; E. Sands, Bruce; Danese, Silvio; D’Haens, Geert; Kaser, Arthur; Panaccione, Remo; T. Rubin, David; Shafran, Ira; McAuliffe, Megan; Kaviya, Arpeat; Sankoh, Serap; Mody, Reema; Abhyankar, Brihad; Smyth, Michael

doi:10.1093/ecco-jcc/jjw176

Public

Long-term Efficacy of Vedolizumab for Crohn’s Disease

Published in Journal of Crohn s and Colitis • Sep 28, 2016

Authors:

Séverine Vermeire

Edward V. Loftus

Jean‐Frédéric Colombel

Abstract

BACKGROUND AND AIMS: Vedolizumab is a gut-selective α4β7 integrin antagonist therapy for ulcerative colitis and Crohn's disease. The GEMINI long-term safety [LTS] trial is an ongoing open-label study investigating the safety of vedolizumab. We present interim exploratory analyses of efficacy in pati...

Subject

Vedolizumab

Crohn's disease

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!